White Willow

Salix alba is a fast-growing deciduous tree native to Europe and western and central Asia, now naturalized in parts of North America. It favors wet ground: riverbanks, floodplains, ditches, and lake margins. Mature trees often reach 15 to 25 meters (sometimes taller), with an open crown and long, flexible branches that can take on a slightly weeping habit.

The common name “white” refers to the leaves. They are narrow and lance-shaped, finely toothed, and covered beneath with silky white hairs that give the canopy a silvery look in wind. Catkins appear in spring with the leaves. The bark of older trunks is gray-brown and deeply fissured; younger twigs are olive to reddish-brown and more supple.

Medicinal willow bark is not limited to S. alba. Pharmacopeial material (often labeled Salicis cortex) may come from several Salix species with meaningful salicylate glycoside content, including S. purpurea, S. daphnoides, S. fragilis, and S. nigra. Species and harvest timing change salicin levels, which is one reason crude teas are harder to dose than standardized extracts.

The part used is typically dried bark collected in spring from young branches, when the inner bark peels more readily and phenolic glycosides are relatively abundant. Leaves have been used in folk practice, but modern herbal products almost always specify bark.

Willow is one of the longest-documented anti-inflammatory plants in the written record. Assyrian medical tablets mention willow for feverish complaints. Egyptian sources describe bark and leaf preparations for joint pain and inflamed wounds. In Chinese medicine, willow has been used for fever, pain, colds, and as a topical wash. Across the Mediterranean, Greek and Roman physicians—including Dioscorides—recommended willow for pain and swelling.

The most frequently retold Western episode is Hippocratic: around the 5th century BCE, patients were advised to chew willow bark or take decoctions to reduce fever and inflammation. Native North American nations independently used local willows (including black willow, Salix nigra) as analgesics and febrifuges, a reminder that salicylate-bearing barks were discovered more than once.

The leap from folk bark to modern drug chemistry happened in the nineteenth century. Crude willow extracts were investigated in the early 1800s. In 1828 Johann Andreas Buchner isolated a yellowish substance he named salicin after Salix. Henri Leroux crystallized salicin from willow bark in 1829. Oxidation pathways from related meadowsweet (Filipendula ulmaria, formerly Spiraea) compounds helped chemists reach salicylic acid. Raffaele Piria and others clarified the relationship between salicin, salicyl alcohol, and salicylic acid.

Salicylic acid reduced fever and pain but burned the stomach. In 1897 Felix Hoffmann, working at Bayer, acetylated salicylic acid to produce acetylsalicylic acid—aspirin—whose name nods to Spiraea. Aspirin did not “come from” chewing willow in a literal manufacturing sense, but willow and meadowsweet supplied the chemical trail. That history still shapes how people talk about white willow: as nature’s prototype for a drug that is now far more standardized, potent, and well studied than the bark itself.

Willow bark never fully disappeared from herbal practice. In Europe it remains a traditional herbal medicinal product for minor joint pain, fever associated with the common cold, and headache, according to the European Medicines Agency’s herbal monograph on willow bark. In North America it is sold as a dietary supplement, most often as capsules or liquid extracts standardized to salicin.

The headline constituent is salicin, a phenolic glycoside. After oral use, gut bacteria and metabolic enzymes help convert salicin toward salicyl alcohol and then salicylic acid. Salicylates can inhibit cyclo-oxygenase (COX) enzymes involved in prostaglandin synthesis, which is the same broad pathway aspirin uses to reduce pain, fever, and inflammation.

It is a mistake to treat milligrams of salicin as equivalent milligrams of aspirin. Aspirin is acetylsalicylic acid; it acetylates COX-1 strongly and has well-characterized antiplatelet effects. Willow’s mix is slower, less potent, and incomplete by comparison. Bark also contains other salicylate glycosides (notably salicortin in many Salix species), flavonoids, condensed tannins, and polyphenols. Some researchers argue these extra constituents contribute anti-inflammatory activity beyond salicin alone, which may help explain why clinical extracts sometimes appear more effective than salicin content would predict.

Because composition varies by species, season, and manufacturing, two products labeled “white willow” can differ substantially. That variability is a safety issue as well as an efficacy issue: you cannot assume a tea matches a 15% salicin extract, and you cannot assume willow is “weaker, therefore safer” than aspirin in someone who cannot take salicylates.

Traditional uses cluster around aches and febrile illness: headache, low back pain, osteoarthritis-type joint pain, myalgia, toothache, and fever with colds. Those indications still dominate product marketing and the EMA’s traditional-use listing.

Modern clinical evidence is modest but not empty. Small trials and reviews have found standardized willow bark extracts (often providing about 120 to 240 mg of salicin per day) may help some adults with chronic low back pain. Osteoarthritis results are mixed; rheumatoid arthritis data are generally unimpressive. A 2014 Cochrane review of herbal medicines for low back pain reported moderate-quality evidence for daily white willow bark in the short term, while noting limited trial size and duration.

NCCIH summarizes the research similarly: willow bark has centuries of use for pain and inflammatory complaints such as bursitis and tendinitis, but only a few small trials support extracts for chronic low-back pain and osteoarthritis. A 2015 phytotherapy review concluded that available evidence plus long traditional use supports analgesic and anti-inflammatory effects, while still calling for better trials.

Willow bark is sometimes promoted for cardiovascular prevention because aspirin is used that way. That leap is not justified. Willow should not be used as a substitute for low-dose aspirin after heart attack, stent, or atrial fibrillation, or for any clinician-directed antiplatelet regimen. Potency is unpredictable, and antiplatelet evidence for bark is not equivalent to aspirin.

Laboratory studies have explored anti-inflammatory and even anticancer activity of willow constituents. Those findings are preliminary and do not support using willow bark to treat cancer or prevent chronic disease.

Commercial products include dried cut bark, teas and decoctions, tinctures, and dry extracts in capsules or tablets. European herbal medicines and many supplements standardize to salicin. Clinical studies that reported benefit typically used extracts delivering 120 to 240 mg salicin daily in adults, for limited periods (often up to about eight weeks in safety reviews).

Traditional decoction uses dried bark simmered in water. Taste is notably bitter and astringent from tannins. Homemade teas are the least predictable form: salicin content is unknown, and tannins may worsen stomach upset. If someone and their clinician choose a product, a clearly labeled extract with salicin content is the more rational option.

EMA guidance for willow bark medicines in the EU is conservative: adults only; no more than four weeks for back or joint pain without professional review; seek care if fever lasts more than three days or headache more than one day while using the product. Those limits reflect the thinness of long-term data, not a claim that four weeks is always safe.

Topical folklore (poultices, washes) exists, but ingested bark is what modern safety discussions address. Do not chew unidentified wild bark. Species identification, pollution along waterways, and dose all matter.

The most common adverse effects in trials are gastrointestinal: nausea, stomach pain, heartburn, vomiting, and diarrhea. Tannins and salicylate activity both irritate some digestive tracts. Dizziness and skin reactions (rash, itching, widespread erythema) are also reported. Frequency is often listed as “not known” in regulatory herb monographs because reporting is incomplete.

A 2019 U.S. Pharmacopeia safety review found no serious adverse events in trials of extracts providing 120 to 240 mg salicin daily for up to eight weeks in adults. That is reassuring for short-term adult use of studied extracts—and it is not a blank check. Those trials excluded children, pregnant people, and other higher-risk groups. Anaphylaxis to willow bark has been reported, though rarely.

Salicin can affect platelet aggregation, generally less strongly than aspirin, but the clinical importance is uncertain in people who already bruise easily, have clotting disorders, or take anticoagulants. Additive bleeding risk is the practical concern. People with salicylate sensitivity can develop asthma flares, hives, or more severe allergic responses.

Overuse or combination with other salicylates increases the chance of salicylate toxicity patterns (ringing in the ears, rapid breathing, severe GI symptoms). Willow is not a good “stack” with aspirin, wintergreen oil, or multiple salicylate herbs.

Do not use willow bark if you have a known allergy or hypersensitivity to salicylates, aspirin, or NSAIDs. Avoid it in aspirin-exacerbated respiratory disease or salicylate-triggered asthma.

Children and adolescents should not take willow bark because of the association between salicylates and Reye syndrome during viral illness. This is the same reason aspirin is restricted in pediatric fever. “Natural” does not change that risk category.

Avoid willow bark in active peptic ulcer disease, significant bleeding or clotting disorders, and severe liver or kidney impairment. EMA also lists glucose-6-phosphate dehydrogenase (G6PD) deficiency among contraindications for willow bark medicines. People with diabetes or gout are often advised to be cautious because salicylates can complicate those conditions; this is a reason to involve a clinician, not to self-experiment.

Pregnancy: salicylates cross the placenta and are cleared slowly in newborns. Willow bark is generally avoided in pregnancy, and European guidance specifically contraindicates use in the third trimester (when NSAID-like drugs can affect fetal circulation). Breastfeeding is also a poor fit given limited safety data and salicylate transfer.

Anyone already advised never to take aspirin should treat willow bark as off-limits unless a clinician who knows that history says otherwise.

The important interactions follow salicylate and antiplatelet logic. Combining willow bark with anticoagulants (warfarin and others), antiplatelet drugs (including aspirin and clopidogrel), or NSAIDs (ibuprofen, naproxen, and related drugs) can increase bleeding and stomach-injury risk. Using several salicylate sources at once does the same.

Alcohol adds gastric irritation and bleeding risk. Herbs that also affect clotting—such as high-dose ginkgo, high-dose fish oil, or garlic extracts—may compound the issue, though evidence quality varies.

Because salicylates can interact with methotrexate, some diabetes medicines, and drugs that compete for renal excretion, people on those therapies need individualized advice. Willow is a poor choice immediately before surgery or dental procedures where bleeding control matters; clinicians often ask patients to stop salicylates in advance.

If a clinician has prescribed daily aspirin, do not add willow bark on top to “get more of the same.” That is how duplicate salicylate exposure happens.